ClearPoint Neuro (ClearPoint Neuro) EV-to-Revenue : 5.32 (As of May. 12, 2024)

View and export this data going back to 2012. Start your Free Trial

What is ClearPoint Neuro EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, ClearPoint Neuro's enterprise value is $139.23 Mil. ClearPoint Neuro's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $26.16 Mil. Therefore, ClearPoint Neuro's EV-to-Revenue for today is 5.32.

The historical rank and industry rank for ClearPoint Neuro's EV-to-Revenue or its related term are showing as below:

CLPT' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.54 Med: 7.28 Max: 38.12
Current: 5.32

During the past 13 years, the highest EV-to-Revenue of ClearPoint Neuro was 38.12. The lowest was 0.54. And the median was 7.28.

CLPT's EV-to-Revenue is ranked worse than
72.64% of 826 companies
in the Medical Devices & Instruments industry
Industry Median: 3.265 vs CLPT: 5.32

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-12), ClearPoint Neuro's stock price is $5.86. ClearPoint Neuro's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $1.05. Therefore, ClearPoint Neuro's PS Ratio for today is 5.57.

ClearPoint Neuro EV-to-Revenue Historical Data

The historical data trend for ClearPoint Neuro's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ClearPoint Neuro EV-to-Revenue Chart

ClearPoint Neuro Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

6.23

21.43

13.73

8.89

6.60

ClearPoint Neuro Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															8.95	7.65	5.07	6.60	6.31

Competitive Comparison of ClearPoint Neuro's EV-to-Revenue

For the Medical Devices subindustry, ClearPoint Neuro's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ClearPoint Neuro's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ClearPoint Neuro's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where ClearPoint Neuro's EV-to-Revenue falls into.

ClearPoint Neuro EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

ClearPoint Neuro's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	139.229	/	26.161
	=	5.32

ClearPoint Neuro's current Enterprise Value is $139.23 Mil.
ClearPoint Neuro's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $26.16 Mil.

ClearPoint Neuro (NAS:CLPT) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

ClearPoint Neuro's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	5.86	/	1.053
	=	5.57

ClearPoint Neuro's share price for today is $5.86.
ClearPoint Neuro's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.05.

ClearPoint Neuro EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of ClearPoint Neuro's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

ClearPoint Neuro (ClearPoint Neuro) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ClearPoint Neuro Inc (NAS:CLPT) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

120 S. Sierra Avenue, Suite 100, Solana Beach, CA, USA, 92075

Website

https://www.clearpointneuro.com

ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use in the United States, is used to perform minimally invasive surgical procedures in the brain and ClearTrace is used to perform minimally invasive surgical procedures in the heart. The company's products and product candidates include ClearPoint neuro system, MRI-guided drug delivery, and Thermal therapy system.

Executives

Lynnette C Fallon	director	108 CHERRY HILL DRIVE, BEVERLY MA 01915
Linda M. Liau	director	120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Mazin Sabra	officer: Chief Operating Officer	120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Joseph Michael Burnett	director, officer: CEO and President	C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618
L. Jeremy Stigall	officer: GM, Biologics & Drug Delivery	120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Danilo D'alessandro	officer: Vice President, Finance	5 MUSICK, IRVINE CA 92618
Harold A Hurwitz	officer: Chief Financial Officer
R John Fletcher	director	C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Girin Pascal E R	director	C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618
B Kristine Johnson	director	366 FERNDALE RD S, WAYZATA MN 55391
Timothy T. Richards	director	ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103
Matthew B. Klein	director	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Marcio Souza	director	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Voyager Therapeutics, Inc.	10 percent owner	75 HAYDEN AVENUE, LEXINGTON MA 02421
Wendelin C Maners	officer: Vice President, Marketing	ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103